Abstract
Biotherapy has emerged as the fourth modality for the treatment of cancer. Biologic response modifiers (BRMs) alter the host-tumor relationship through immunomodulation to affect a biologic response. Currently, two BRMs, alpha-interferon and interleukin-2, have had clinical success in treating cancer and have gained approval by the U.S. Food and Drug Administration. Toxicities associated with BRMs are complex and often involve multiple systems. Understanding these toxicities and their corresponding pathophysiologic manifestations aides nurses in their assessment and management of patients receiving BRMs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
